key: cord-0295470-u2bptjyo
authors: Chaudhuri, Arka Sen; Yeh, Yu-Wen; Sun, Jia-Bin; Zewdie, Olifan; Jin, Tao; Wei, Bin; Holmgren, Jan; Xiang, Zou
title: S100A4 exerts robust mucosal adjuvant activity for co-administered antigens in mice
date: 2022-01-04
journal: bioRxiv
DOI: 10.1101/2022.01.04.474916
sha: 5d5ec49375e93970a9ba034a8ff86e998920fa97
doc_id: 295470
cord_uid: u2bptjyo

The lack of clinically applicable mucosal adjuvants is a major hurdle in designing effective mucosal vaccines. We hereby report that the calcium-binding protein S100A4, which regulates a wide range of biological functions, is a potent mucosal adjuvant in mice for co-administered antigens, including the SARS-CoV-2 spike protein, with comparable or even superior efficacy as cholera toxin but without causing any adverse reactions. Intranasal immunization with recombinant S100A4 elicited antigen-specific antibody and pulmonary cytotoxic T cell responses, and these responses were remarkably sustained for longer than six months. As a self-protein, S100A4 did not stimulate antibody responses against itself, a quality desired of adjuvants. S100A4 prolonged nasal residence of intranasally delivered antigens and promoted migration of antigen-presenting cells. S100A4-pulsed dendritic cells potently activated cognate T cells. Furthermore, S100A4 induced strong germinal center responses revealed by both microscopy and mass spectrometry, a novel technique for measuring germinal center activity. In conclusion, S100A4 may be a promising adjuvant in formulating mucosal vaccines, including vaccines against pathogens that infect via the respiratory tract, such as SARS-CoV-2.

The COVID-19 pandemic, caused by the virus SARS-CoV-2, continues to be a major 48 global health menace. As vaccination is considered the most cost-effective strategy for the 49 control of infectious diseases, strategies to control the COVID-19 pandemic by developing However, a hurdle for a wider use of mucosal vaccination is that with most purified 64 antigens, successful immunization will usually require co-administration with an effective 65 mucosal adjuvant. There is, as yet, a scarcity of safe and effective mucosal adjuvants for 66 human use. Cholera toxin (CT) is the most potent and best characterized "gold standard" 67 mucosal adjuvant used in experiments on animals but is too toxic for humans. We have 68 recently identified a critical role for the calcium-binding protein S100A4 in the mucosal 69 adjuvanticity of CT by demonstrating that endogenous S100A4 is required for CT's ability 70 to adjuvant both humoral and cellular adaptive immune responses following mucosal 71 immunization (Sun et al., 2017) . Mice that were genetically deficient in S100A4 mounted 72 severely compromised antigen-specific immune responses, which were associated with 73 dampened antigen presentation by dendritic cells (DCs), reduced T cell activation, and a 74 lack of germinal center formation. Notably, the engraftment of wild-type DCs in the 75 S100A4-deficient mice prior to mucosal immunization with the antigen, together with CT, 76 almost fully restored the defective immune responses, indicating that the expression of 77 S100A4 by DCs and possibly other antigen-presenting cells is critical for mounting an 78 effective adaptive immune response (Sun et al., 2017) . 79 80 S100A4 is one of more than 20 calcium-binding proteins collectively categorized as the 81 S100 protein family (Gross et al., 2014) . S100A4 was originally described as fibroblast-82 specific protein 1 (FSP1) because of its restricted expression to stromal fibroblasts (Strutz 83 et al., 1995) . However, this protein was later found to have a much wider expression 84 spectrum, being expressed also by at least endothelial cells, smooth muscle cells, 85 lymphocytes, neutrophils, macrophages, and DCs (Boomershine et al., 2009, Li et al., 86 2010, Mishra et al., 2012) . S100A4 interacts with cellular targets through at least two 87 receptors: the receptor for advanced glycation end-products (RAGE) and toll-like receptor 88 4 (TLR4) (Boye et al., 2008 , Cerezo et al., 2014 . S100A4 has the capacity to regulate a 89 diverse range of cellular processes, such as cell growth, survival, differentiation, and 90 motility (Donato et al., 2013) . We have previously revealed a critical role of S100A4 in 91 adaptive immune responses (Bruhn et al., 2014 , Sun et al., 2017 .

In this study, we examined the potential of using purified exogenous S100A4 as a mucosal 94 adjuvant in its own right for co-administered antigens. Our results demonstrate that when 95 given intranasally, together with either ovalbumin (OVA), as an experimental vaccine 96 antigen, or the spike protein of SARS-CoV-2, as a clinically applicable vaccine antigen, 97 S100A4 can, without any adverse reactions, effectively augment antigen-specific humoral 98 immune responses both mucosally and systemically, as well as stimulate antigen-specific 99 cytotoxic T cell responses in the lungs, to levels comparable to or better than those using 100 CT as adjuvant. Remarkably, these antigen-specific adaptive immune responses were 101 sustained for longer than six months. We also introduced a novel, label-free matrix-assisted 102 laser desorption/ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS) 103 technique for the detection of S100A4-induced germinal center responses in the spleen.

Exogenous S100A4 is a strong mucosal adjuvant 106 Based on our previous findings of endogenous S100A4 being critical for the in vitro 107 antigen-presenting capacity of DCs, and for the in vivo mucosal adjuvant effect of CT (Sun 108 et al., 2017), we wished to examine whether exogenous S100A4 might also work as a 109 mucosal adjuvant in its own right. We tested this by immunizing mice intranasally on three 110 occasions with a model antigen, OVA, administered with or without S100A4, and for 111 comparison in a separate group of mice also with CT, and by examining immune responses 112 three days after the last dose ( Supplementary Fig. 1a) . Serum anti-OVA total IgG, IgG1, 113 and IgG2c levels were all robustly augmented after immunization together with S100A4, 114 to levels comparable to those achieved using CT as adjuvant ( Supplementary Fig. 1b ). 115 S100A4 also potentiated mucosal antibody production in mucosal tissues, resulting in 116 strongly enhanced OVA-specific IgA, total IgG, and IgG1 antibody levels in lung exudate 117 ( Supplementary Fig. 1c) . Importantly, the intranasal co-administration with S100A4 118 further resulted in enhanced antigen-specific IgA and IgG responses at a remote site, the 119 vaginal mucosal surface ( Supplementary Fig. 1d) , consistent with previous studies showing 120 a nasal-genital tract mucosal immunological link (Czerkinsky & Holmgren, 2010) . Similar 121 to the serum antibody responses, the immunization with S100A4 also promoted mucosal 122 antigen-specific antibody production to levels comparable to those achieved by using CT 123 as adjuvant ( Supplementary Fig. 1 ).

Next, we largely repeated this experiment but halved the amount of S100A4 (10 µg per 126 dose) and extended the antibody measurement to as long as 196 days (roughly 6.5 months) 127 after the last immunization ( Fig. 1a) . At this substantially late time point, serum anti-OVA 128 IgG antibody responses, including total IgG, IgG1, and IgG2c, remained high in S100A4-129 adjuvanted mice, not much less compared to a much earlier time point, 10 days after the 130 last dose of immunization (Fig. 1b) . Furthermore, mucosal anti-OVA IgG and IgA levels, 131 in lung exudate (Fig. 1c) , bronchoalveolar lavage fluid (BALF) (Fig. 1d) , vaginal lavage 132 (Fig. 1e) , and feces (Fig. 1f) , remained substantially high at this late time point in mice 133 which received OVA admixed to S100A4. The S100A4-driven antibody sustainability was 134 comparable to CT-adjuvanted immunization ( Fig. 1b-f ). These late time point mucosal 135 antibody levels were also found to be sustained in comparison to the levels in previous 136 experiments measured at an earlier time point (Supplementary Fig. 1c and d) , despite a 137 higher dose of S100A4 being used in that immunization (20 µg per dose). 138 We also determined the accumulation of OVA257-264 peptide (SIINFEKL)-specific CD8 T 139 cells in various tissues using the H-2K b -SIINFEKL tetramer analyzed by flow cytometry 140 ( Supplementary Fig. 2 ). Co-administration with S100A4 promoted the expansion of CD8 T 141 cells that recognized the MHC class I-associated SIINFEKL peptide in the lung (Fig. 1g) , 142 lymph node (Fig. 1h) , and spleen ( Fig. 1i ) at 10 days after the last immunization. A trend 143 of enhanced expansion of these T cells in the lymph nodes and spleen was observed when 144 comparing the effect of S100A4 with CT ( Fig. 1h and i) . For SIINFEKL peptide-specific T 145 cell expansion in the lung, we also measured at 196 days after the last immunization, and 146 S100A4-adjuvanted immunization maintained the response better than CT (Fig. 1g) . These 147 findings suggest that S100A4 could be helpful in driving cytotoxic T cell responses, in 148 addition to stimulating humoral immunity, and may exert a critical role in maintaining 149 protective immunity against viral infections.

To examine if the mucosal adjuvant activity of S100A4 on the immune response to the 151 model antigen OVA would extend to a clinically relevant vaccine antigen, such as the 152 spike protein of SARS-CoV-2 ("Spike"), we immunized mice with Spike alone or together 153 with either S100A4 or CT as adjuvants using a similar intranasal immunization regimen as 154 with OVA (Fig. 2a) . Again, co-immunization with S100A4 resulted in substantially 155 increased levels of Spike-specific total IgG and IgG1 antibodies in serum (Fig. 2b) , as well 156 as Spike-specific mucosal IgA responses in BALF (Fig. 2c) , lung parenchyma (Fig. 2d) , 157 nasal mucosa (Fig. 2e) , and eye mucosa (Fig. 2f ). It has recently been reported that Using in vitro cultured bone marrow-derived DC (BMDC), we failed to observe any 208 augmentation in the uptake of fluorescent OVA after treatment with either S100A4 or CT 209 ( Supplementary Fig. 4a) . Similarly, uptake of fluorescent OVA by fresh ex vivo cells from 210 the nasal tissue, cervical lymph nodes, and spleen was not enhanced by S100A4 or CT 211 ( Supplementary Fig. 4b) . Thus, it is likely S100A4 promoted the migration of antigen-212 presenting DCs from the nasal mucosa but did not promote antigen uptake itself. Our in 213 vivo imaging data showing S100A4-promoted antigen accumulation in the nasal tissue, 214 cervical lymph nodes and lung tissues after nasal delivery of the antigen (Fig. 3d-f ) 215 support a stimulatory effect of S100A4 in promoting the migration of antigen-presenting 216 cells including DCs and macrophages that had captured the antigen after mucosal delivery.

To fundamentally confirm the effect of S100A4 on DC migration, we designed an adoptive 218 transfer assay to unambiguously demonstrate more efficient DC migration driven by 219 S100A4. S100A4-primed and control BMDCs were labelled with a green fluorescent dye 220 for easy tracking. Following injection of the fluorescent DCs into the mouse footpad, 221 substantially increased numbers of fluorescent DCs that had been previously treated with 222 S100A4 arrived in the draining lymph nodes compared with the control DC (Fig. 3g ). in both the spleen and cervical lymph nodes of mice that received the antigen together with 232 S100A4 (Fig. 4a) . In both compartments, S100A4 also expanded germinal center B cells 233 (GL7 + FAS + CD38 -B220 + ) (Fig. 4b) and T follicular helper cells (PD-234 1 + CXCR5 + CD4 + Foxp3 -), a cell type which is critical in the formation of germinal centers 235 (Fig. 4c) . The immune enhancing effects of S100A4 were similar to those of CT (Fig. 4 a-236 c). These results were confirmed using immune staining and confocal microscopy to 237 demonstrate the typical germinal center morphology. Mouse spleens were first 238 cryosectioned, followed by immunofluorescent staining for the expression of B220, GL7, 239 as well as the cell proliferation marker Ki-67, as previously reported (Sun et al., 2017) . 240 Immunization with S100A4 strongly promoted the expansion of GL7 + and Ki-67 + B cells 241 and morphological changes associated with germinal center formation (Fig. 4d) . were identified in the spleens (Supplementary Fig. 6) . A shotgun lipidomics approach was 252 used to analyze all lipid classes together. The abundance of total lipids was increased in the 253 spleen after co-immunization with S100A4 (Fig. 5a) . The lipid intensities were quantified 254 and expressed using an intensity box plot which displayed a remarkable increase of lipids 255 13 in spleens from S100A4-adjuvanted mice (Fig. 5b) . Principal component analysis revealed 256 a complete separation of S100A4-adjuvanted immunization from both the OVA only 257 immunization and the naïve mouse controls (Fig. 5c) . A similar and more intense lipid 258 accumulation response than that induced by S100A4 was seen in mice given CT together 259 with OVA (Fig. 5) . Extracellular S100A4 potentiates DC activation 269 DCs are critical antigen-presenting cells that bridge innate and adaptive immune responses 270 and, as such, are rational targets for the choice of effective adjuvants (Tesfaye et al., 2019) . 271 We have previously demonstrated that adoptive engraftment of wild-type DCs could 272 restore the defective adaptive immune responses of S100A4-deficient mice (Sun et al., 273 2017). Here we examined the regulatory effect of exogenous S100A4 on cultured DCs.

Our data clearly demonstrates that mRNA expression of a group of cytokines and 275 molecules with immune regulatory activities was upregulated in BMDCs following 276 incubation with S100A4 (Fig. 6a) . Specifically, the transcript levels of a number of 277 cytokines that are critical to adaptive immunity, including IL-1b, IL-2, IL-6, and IL-10, 278 were augmented after treatment with S100A4, as were co-stimulatory molecules, including 279 CD80, CD86, and CD40. Furthermore, at the protein level, S100A4 was found to potently 280 activate BMDCs by augmenting the production of these costimulatory molecules, as well 281 as IL-1b and IL-6 (Fig. 6b) .

We have previously shown a dependence on NFκB signaling as a critical DC activation 284 pathway used by CT to exert mucosal adjuvant activity (Terrinoni et al., 2019) . Here, we 285 can also demonstrate that S100A4-mediated DC activation is at least partially dependent 286 on NFkB signaling. Thus, S100A4-induced production of IL-1b, a critical molecule in the 287 pathway of adjuvanticity, was substantially suppressed in NFκB -/-BMDCs, although the 288 increased expression of CD80 and CD86 by S100A4 remained intact in NFκB -/cells (Fig.   289 6c). The latter finding may suggest that S100A4 could have a broader spectrum of 290 signaling pathways than CT, which failed to increase both costimulatory molecule 291 expression and IL-1b production in NFκB -/-BMDCs (Fig. 6c) . Extracellular S100A4 has 292 been shown to activate NFkB in various types of cells (Boye et al., 2008 , Kim et al., 2017 Schmidt -Hansen et al., 2004) . Therefore, it is not surprising that S100A4, as shown here, 294 also stimulates DCs through the NFkB pathway. It is reported that S100A4 triggers intracellular signaling pathways through RAGE and 297 TLR4 (Bjork et al., 2013) . Indeed, BMDCs expressed both RAGE and TLR4 (Fig. 6d) , and 298 we found that RAGE expression was upregulated by exogenous S100A4 (Fig. 6e ). We 299 then tested whether S100A4-mediated DC activation would require either or both of these 300 two receptors. To this end, BMDCs were incubated with S100A4 either in the presence or 301 absence of FPS-ZM1, an inhibitor of RAGE, or TAK-242, an inhibitor of TLR4, and the 302 effects on CD86 expression as well as production of IL-1b were measured. The results 303 showed that S100A4-induced upregulation of both of these activation markers was almost 304 completely abrogated by blocking either RAGE or TLR4 (Fig. 6f) , suggesting the 305 requirement of both receptors for S100A4-induced DC activation. 306 307 Extracellular S100A4 enhances MHC class I antigenic peptide cross-presentation by 308 DC and activation of cytotoxic T cells 309 We have demonstrated the potent effect of S100A4 in stimulating cytotoxic CD8 T cells 310 against a co-administered antigen (Fig. 1g-i) . Next, we wished to also confirm that 311 S100A4 could enhance MHC class I-associated antigenic peptide cross-presentation on 312 DCs, a critical step in the activation of cytotoxic T cell responses after immunization with 313 protein-based subunit vaccines (Ho et al., 2018) . To this end, we incubated OVA-pulsed 314 DCs either in the presence or absence of S100A4, followed by co-culturing the DCs with 315 RF33.70 hybridoma T cells that had T cell receptors specific for OVA257-264 presented by 316 H2K b . S100A4-pulsed DCs substantially augmented the activation of T cells as measured 317 by IL-2 production (Fig. 6g) . S100A4 demonstrated a more potent effect compared with 318 CT (Fig. 6g) .

The adjuvanticity of S100A4 is not affected by contaminating lipopolysaccharide 320 (LPS) 321 We performed both in vivo immunization and in vitro DC activation assays to rule out the 322 possible confounding effect of a residual low amount of endotoxin present in the 323 recombinant S100A4 product (10 pg LPS per µg S100A4, as measured using a Limulus 324 amebocyte lysate assay). In vivo, mice were given three intranasal immunizations at ten-325 day intervals with OVA in the presence of various doses of S100A4 or various amounts of 326 LPS corresponding to the residual LPS amount in a given S100A4 dose. Ten days after the 327 last immunization, blood was collected and OVA-specific total IgG antibody production in 328 serum was measured. The tested range of LPS amounts failed to promote OVA-specific 329 IgG production, supporting that the enhancement of this response by S100A4 is a true Fig. 8a ).

In the in vitro experiments, we incubated BMDCs with LPS at 10 pg/ml, i.e. the estimated 336 contamination level of LPS in 1 µg/ml S100A4, which was tested in parallel, and observed 337 no enhancement in the expression of the genes under study (Supplementary Fig. 8b) . In 338 contrast, a 100,000-fold higher level of LPS (1 µg/ml) demonstrated potent stimulatory 339 effects ( Supplementary Fig. 8b ). Further support for the S100A4 protein, but not the 340 residual endotoxin contamination, being the entity responsible for DC activation came 341 from studies showing that the strong promotion of CD80, CD86 and IL-1b in BMDCs by 342 the recombinant S100A4 was largely suppressed by a neutralizing antibody against 343 S100A4 ( Supplementary Fig. 8c ). preferably be avoided. To assess the quality of S100A4 in this respect, we repeated our 351 basic intranasal immunization model using OVA as an experimental antigen admixed with 352 either S100A4 or CT as an adjuvant ( Supplementary Fig. 9a) . Consistent with the previous 353 findings (e.g., Supplementary Fig. 1b and Fig. 1b) , we again showed that both S100A4 and 354 CT were able to remarkably augment anti-OVA IgG levels ( Supplementary Fig. 9b and c) . 355 Interestingly, while CT, as a foreign protein, stimulated substantial levels of anti-CT IgG 356 antibody responses ( Supplementary Fig. 9c) , S100A4 failed to stimulate anti-S100A4 IgG 357 antibody production above the level seen in naïve mice ( Supplementary Fig. 9b ). This 358 could be due to the fact that S100A4 is an internal protein subject to immune tolerance. 359 The data suggests that S100A4 could lead to improved tolerability over non-host proteins 360 (e.g., CT) in repeated use as a vaccine adjuvant. Although for safety reasons, these toxins are not suitable as mucosal adjuvants in humans 367 (Lycke, 2012) , CT has been extensively studied and is considered the "gold standard" 368 experimental mucosal adjuvant (Sanchez & Holmgren, 2011) . Therefore, CT is commonly 369 used as a benchmark for comparing the adjuvant effects of other candidate mucosal 370 adjuvants. Various approaches have been attempted to modify these native bacterial toxins 371 to derive mutants that can be used clinically (Lycke & Lebrero-Fernandez, 2018 ). Yet, 372 toxin-independent approaches are also worth exploring. In this study, we present 373 experimental evidence that nasal immunization with protein antigens adjuvanted with 374 S100A4 induced adaptive immune responses comparable, or superior, in magnitude to 375 those achieved using CT as an adjuvant. S100A4 augmented antigen-specific immune 376 responses, both systemically and at mucosal surfaces, to intranasally co-administered 377 antigens without any adverse effects, as shown using both OVA as a model antigen and the 378 SARS-CoV-2 spike protein as a clinically applicable vaccine antigen. Furthermore, 379 S100A4 potently induced the expansion of antigen-specific CD8 T cells, which could 386 387 S100A4 is a member of the damage-associated molecular pattern (DAMP) family 388 (Bertheloot & Latz, 2017) . This heterogeneous family is composed of proteins, lipids, 389 nucleic acids, and small-molecule compounds that are normally sequestered inside cells 390 but are released upon stress stimulation, e.g., tissue injury (Venereau et al., 2015) . DAMP 391 molecules have been implicated in the activation of inflammasomes (Lage et al., 2014) , a 392 process used by many adjuvants (Ivanov et al., 2020) . We have previously demonstrated 393 that DCs from mice lacking S100A4 have compromised inflammasome-associated 394 caspase-1 and IL-1β production upon treatment with CT (Sun et al., 2017) . In the present 395 study, we show that extracellular S100A4 can promote not only the upregulation of critical 396 costimulatory molecules in DCs, including CD80, CD86, and CD40, but also the 397 production of key cytokines, including IL-1b, for the induction and maintenance of 398 adaptive immunity. The generation of IL-1b by DCs and other APCs as a consequence of 399 NFkB activation and an inflammasome response has been found to be a critical step in the 400 adjuvant function of CT (Terrinoni et al., 2019) . Taken together, our work suggests not 401 only an endogenous effect of S100A4 in mucosal immunization (Sun et al., 2017) , but also 402 that, as a secreted protein (Schmidt-Hansen et al., 2004) , S100A4 may have a paracrine or 403 endocrine function on cells including APCs, which is likely further enhanced by the 404 exogenous S100A4 added as an adjuvant.

In addition to the possible induction of mucosal tolerance, poor uptake and rapid clearance 407 by mucociliary movement of the antigen at the nasal mucosal surface have been described 408 as hurdles for developing effective nasal immunization strategies (Gizurarson, 2015) . 409 Various types of mucoadhesive agents have been co-administered with the antigens to 410 improve nasal retention and antigen uptake (Jabbal-Gill, 2010) . Chitosan, as a 411 biocompatible and biodegradable natural polymer, has been extensively investigated as a 412 safe and effective mucoadhesive for improving nasal vaccine delivery (Kang et al., 2009 ). 413 Interestingly, as shown here, S100A4, in addition to its potent immune stimulatory effect, 414 remarkably prolonged the nasal residence time of co-administered fluorescent OVA. This 415 effect is likely due to the calcium-binding activity of S100A4, since free calcium is critical 416 for maintaining the ciliary beating frequency (Schmid & Salathe, 2011) , and restricted 417 ciliary beating may lead to a prolonged antigen residence time. In addition to prolonging 418 the mucosal antigen retention time, our data also suggests that S100A4 can promote DC 419 migration from the nasal mucosa. The latter effect may depend on the ability of S100A4 to 420 both increase and engage RAGE on DCs, insofar as it has been previously observed that 421 DCs depend on RAGE for their in vivo homing to lymph nodes (Manfredi et al., 2008) .

We further demonstrated that nasal co-administration of an antigen with S100A4 strongly Strutz et al., 1995) . Furthermore, S100A4 has been found to be critical in maintaining the 449 normal biological functions of various types of cells through regulating cell growth, 450 survival, differentiation, and motility (Donato et al., 2013) . We note here that clinically-451 oriented research on S100A4 has largely focused on its cancer metastasis-promoting 452 properties (Boye & Maelandsmo, 2010 , Mishra et al., 2012 . However, this does not 453 preclude its applicability as an adjuvant in vaccination, as there is no evidence that 454 exogenous S100A4 can induce cancer metastasis, and, on the contrary, S100A4 is also 455 found to exert anticancer activity (Dukhanina et al., 2018) . Importantly, we did not 456 observe any obvious side effects either shortly after or more than six months after nasal 457 administration with S100A4. Therefore, we believe that S100A4, as a human endogenous 458 protein, may have an advantageous safety profile compared with microbial pathogen-459 associated molecular pattern (PAMP) molecules, which have been extensively tested for 460 possible modification as a mucosal adjuvant (Demento et al., 2011) . Notwithstanding this 461 assumption, rigorous safety evaluations must be undertaken before S100A4 can be used 462 clinically as a vaccine adjuvant. (1 µg/ml), or LPS (Sigma-Aldrich) (10 pg/ml or 1 µg/ml), for specified time 510 periods at 37°C in 5% CO2, followed by washing and re-suspension in buffer for flow 511 cytometric examination or RNA purification. Where indicated, an anti-S100A4 antibody 512 (clone 6B12) (Klingelhofer et al., 2012) or isotype control was used to block functional 513 S100A4 extracellularly. To investigate whether the surface expression of the receptors 514 RAGE and TLR4 were required for S100A4 to activate DCs, BMDCs were incubated 515 overnight with S100A4 or S100A4 pre-mixed with FPS-ZM1 (10 µM; Sigma-Aldrich) or Results were analyzed using Living Image 4.7.3 (Perkin Elmer). Naïve mice were used to 538 adjust settings for eliminating background fluorescence.

In vivo migration assay 541 To investigate DC migration, BMDCs were treated with or without S100A4 (1 µg/ml) 

Confocal images were acquired using a TCS SPE confocal microscope (Leica) with a 60 × 574 zoom. The data were analyzed using LAS X Leica software (Leica). Quantitative reverse transcription PCR (RT-qPCR) 591 Total RNA was isolated using an RNeasy Mini Kit (Qiagen). cDNA was synthesized using 592 a RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). The generated 593 cDNA was used as a template for RT-qPCR, which was performed with a ViiA™ 7 Real-594 Time PCR System (Applied Biosystems) using a PowerUp™ SYBR™ Green Master Mix 595 (Thermo Fisher Scientific). PCR was carried out with an initial incubation at 50°C for 2 596 min, 95°C for 2 min, and then 40 cycles of 95°C for 15 s and 60°C for 1 min. The 597 specificity of the reaction was verified by melt-curve analysis. The 2 -DDCt method was 598 employed to calculate relative gene expression levels. GAPDH was amplified as an 599 internal control. The forward and reverse primers for GAPDH were 5'-600 Data availability 626 This study includes no data deposited in external repositories. 

GGTGAAGGTCGGTGTGAACGGA-3' and 5'-TGTTAGTGGGGTCTCGCTCCTG-3'

601 for IL-1b 5'-GGAGAACCAAGCAACGACAAAATA-3' and 5'-602 TGGGGAACTCTGCAGACTCAAAC-3'; for IL-2 5'-603 CCTGAGCAGGATGGAGAATTACAT-3' and 5

604 for IL-6 5'-CCACTTCACAAGTCGGAGGCTTA-3' and 5'-605 CCAGTTTGGTAGCATCCATCATTTC-3'; for IL-10 5'-606 GCCAGAGCCACATGCTCCTA-3' and 5'-GATAAGGCTTGGCAACCCAAGTAA -3

607 for CD86 5'-TCCTGTAGACGTGTTCCAGA-3' and 5'-608 TGCTTAGACGTGCAGGTCAA-3'; for CD80 5'-GGTATTGCTGCCTTGCCGTT-3' 609 and 5'-TCCTCTGACACGTGAGCATC-3'

GTGGTACAATCATCAGTTGGG-3'; for 612 IL-10 5'-GCCAGAGCCACATGCTCCTA-3' and 5'-613 GATAAGGCTTGGCAACCCAAGTAA -3'; and for TNF-a 5'-614 AAGCCTGTAGCCCACGTCGTA-3' and 5

U test or Student's t-test was used to calculate statistical differences 618 between different treatment conditions. Comparisons involving multiple groups were 619 performed using 2-way ANOVA with Bonferroni's multiple comparison test

Wallis test, a non-parametric method, was used for MALDI-TOF data analysis. All the 621 statistical analyses were calculated using Prism software 7. In all the statistical significance 622 comparisons we have provided the exact P-values except for those

University of Massachusetts, for providing the RF33.70 cell line. We thank the 632 staff at the Centralized Animal Facilities (CAF) and University Research Facility in Life 633

ULS) at the Hong Kong Polytechnic University for valuable technical support

This work was supported by the Hong Kong Polytechnic University Internal Research 635

the NSFC/RGC Joint Research Scheme of the Research Grant Council 636 of Hong Kong (N_PolyU533/19) and the National Natural Science Foundation of China 637 (81961160738), PolyU Lean Launchpad Programme, and the Greater Bay Area 638 International Institute for Innovations (GBA I3) Postdoc Programme

Adjuvants Enhance the Induction of Germinal Center

Antibody Secreting Cells in Spleen and Their Persistence in Bone Marrow of Neonatal Mice

IL-1alpha, IL-33 and S100 proteins: dual-function 660 alarmins

Common interactions between S100A4 and S100A9 defined by a novel 663 chemical probe

Accelerated COVID-19 vaccine development: 665 milestones, lessons, and prospects

Autoimmune pancreatitis results 668 from loss of TGFbeta signalling in S100A4-positive dendritic cells

Activation of NF-kappaB by 671 extracellular S100A4: analysis of signal transduction mechanisms and identification of target 672 genes

S100A4 and metastasis: a small actor playing many roles

A generally applicable translational strategy identifies 679 S100A4 as a candidate gene in allergy

The metastasis-associated protein S100A4 promotes the 683 inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid 684 arthritis

Topical immunization strategies

Pathogen-associated 688 molecular patterns on biomaterials: a paradigm for engineering new vaccines

Functions of S100 691 proteins

The role of S100A4 protein in 693 anticancer cytotoxicity: its presence is required on the surface of 694 CD(4+)CD(25+)PGRPs(+)S100A4(+) lymphocyte and undesirable on the surface of target cells

The effect of cilia and the mucociliary clearance on successful drug 697 delivery

Joining S100 proteins and migration: for 699 better or for worse, in sickness and in health

Adjuvants Enhancing Cross-702 Presentation by Dendritic Cells: The Key to More Effective Vaccines? Front Immunol

Controlling timing and location in vaccines

Inflammasomes as Targets for 707

Nasal vaccine innovation

Metabolism as a guiding force for immunity

Application of chitosan microspheres for nasal delivery of 713 vaccines

Migratory 715 dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph 716 node contraction

Extracellular S100A4 718 negatively regulates osteoblast function by activating the NF-kappaB pathway

Anti-S100A4 antibody suppresses metastasis formation by blocking 722 stroma cell invasion

Emerging 724 Concepts about NAIP/NLRC4 Inflammasomes

S100A4 regulates macrophage 727 chemotaxis

Vaccine priming is restricted to 731 draining lymph nodes and controlled by adjuvant-mediated antigen uptake

Nasal route for vaccine and drug delivery: Features and current 734 opportunities

Is the choice of vaccine adjuvant critical for long-term memory development? 736

Recent progress in mucosal vaccine development: potential and limitations

ADP-ribosylating enterotoxins as vaccine adjuvants

Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes

Mucosal vaccines and technology

S100A4 calcium-binding protein is key player in 749 tumor progression and metastasis: preclinical and clinical evidence

Mouse CD38 is down-regulated on germinal center B 752 cells and mature plasma cells

Generation of class I MHC-restricted T-T hybridomas

Cholera toxin -a foe & a friend

Ciliary beat co-ordination by calcium

Extracellular S100A4(mts1) stimulates invasive growth of mouse 761 endothelial cells and modulates MMP-13 matrix metalloproteinase activity

The Use of 764 Principal Component Analysis in MALDI-TOF MS: a Powerful Tool for Establishing a Mini-765 optimized Proteomic Profile

B cell primary immune responses

IgA dominates the early neutralizing antibody response to 771 SARS-CoV-2

773 Identification and characterization of a fibroblast marker: FSP1

Induction of mucosal immunity through systemic 776 immunization: Phantom or reality?

Plasma cell and memory B cell differentiation from the 779 germinal center

Calcium-Binding Protein S100A4 Impairs the Adjuvant Action of Cholera Toxin

Requirement for Cyclic AMP/Protein 784

Dependent Canonical NFkappaB Signaling in the Adjuvant Action of Cholera Toxin 785 and Its Non-toxic Derivative mmCT

Targeting Conventional Dendritic Cells 787 to Fine-Tune Antibody Responses

DAMPs from Cell Death to New Life

Enhanced SARS-CoV-2 793 neutralization by dimeric IgA

Germinal center B cells selectively oxidize fatty acids for energy while 800 conducting minimal glycolysis

 629 We thank N.S. Li, Guangzhou Medical University, for technical assistance; C. Deng, C.M.

Wong, Hong Kong Polytechnic University, for helpful advice on lipid metabolism; and